SYK-3BP2 Pathway Activity in Parenchymal and Myeloid Cells Is a Key Pathogenic Factor in Metabolic Steatohepatitis-Reference-Cited by-同舟云学术

SYK-3BP2 Pathway Activity in Parenchymal and Myeloid Cells Is a Key Pathogenic Factor in Metabolic Steatohepatitis

Published:2022 Issue:1 Volume:13 Page:173-191
ISSN:2352-345X
Container-title:Cellular and Molecular Gastroenterology and Hepatology
language:en
Short-container-title:Cellular and Molecular Gastroenterology and Hepatology

Author:

Luci Carmelo,Vieira Elodie,Bourinet Manon,Rousseau Déborah,Bonnafous Stéphanie,Patouraux Stéphanie,Lefevre Lauren,Larbret Frederic,Prod’homme Virginie,Iannelli Antonio,Tran Albert,Anty Rodolphe,Bailly-Maitre Béatrice,Deckert Marcel,Gual Philippe^ORCID

Funder

ANR

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference66 articles.

1. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease;Eslam;Gastroenterology,2020

2. Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes;Younossi;Hepatology,2016

3. The global obesity pandemic: shaped by global drivers and local environments;Swinburn;Lancet,2011

4. Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases;Samuel;Cell Metab,2018

5. Diabetes mellitus predicts occurrence of cirrhosis and hepatocellular cancer in alcoholic liver and non-alcoholic fatty liver diseases;Raff;J Clin Transl Hepatol,2015

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring Key Genes with Diagnostic Value for Nonalcoholic Steatohepatitis Based on Bioinformatics Analysis;ACS Omega;2023-05-30

2. PARsylation-mediated ubiquitylation: lessons from rare hereditary disease Cherubism;Trends in Molecular Medicine;2023-05

3. Immune cells and their derived microRNA-enriched extracellular vesicles in nonalcoholic fatty liver diseases: Novel therapeutic targets;Pharmacology & Therapeutics;2023-03

4. The spleen tyrosine kinase (SYK): A crucial therapeutic target for diverse liver diseases;Heliyon;2022-12

5. Metabolic Fatty Liver Disease in Children: A Growing Public Health Problem;Biomedicines;2021-12-14